(Q45141064)

English

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Francesco Caponigro

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Pax Willemse

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Roberto Sorio

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Anne Floquet

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Simon van Belle

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Jan Demol

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Rosa Tambaro

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Alessandro Comandini

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Angela Capriati

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sabine Adank

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Jantien Wanders

11

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

85-89

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

https://scigraph.springernature.com/pub.10.1023/b:drug.0000047110.36382.45

0 references

Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of refractory and recurrent ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/B:DRUG.0000047110.36382.45

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45141064&oldid=2066968255"